Literature DB >> 27695908

Reply to Rahbar K et al.

Madhav Prasad Yadav1, Sanjana Ballal1, Madhavi Tripathi1, Chandrasekhal Bal2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27695908     DOI： 10.1007/s00259-016-3531-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  12 in total

1.  18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.

Authors:  Steven M Larson; Lawrence H Schwartz
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

2.  Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.

Authors:  Giuseppe Di Lorenzo; Carlo Buonerba; Adriana Faiella; Pasquale Rescigno; Mimma Rizzo; Riccardo Autorino; Sisto Perdonà; Nando Riccardi; Sarah Scagliorini; Florinda Scognamiglio; Daniele Masala; Matteo Ferro; Giovannella Palmieri; Michele Aieta; Alfredo Marinelli; Vincenzo Altieri; Sabino De Placido; Giacomo Cartenì
Journal:  BJU Int       Date:  2011-01       Impact factor: 5.588

3.  177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment.

Authors:  Madhav Prasad Yadav; Sanjana Ballal; Madhavi Tripathi; Nishikant Avinash Damle; Ranjit Kumar Sahoo; Amlesh Seth; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-10       Impact factor: 9.236

4.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.

Authors:  Martina Benešová; Martin Schäfer; Ulrike Bauder-Wüst; Ali Afshar-Oromieh; Clemens Kratochwil; Walter Mier; Uwe Haberkorn; Klaus Kopka; Matthias Eder
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

5.  Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer.

Authors:  Matthew D Schmitz; Gilbert D A Padula; Patrick Y Chun; Alan T Davis
Journal:  Radiat Oncol       Date:  2010-09-16       Impact factor: 3.481

Review 6.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

7.  The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival.

Authors:  Elizabeth A Kidd; Barry A Siegel; Farrokh Dehdashti; Perry W Grigsby
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

8.  177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

Authors:  Richard P Baum; Harshad R Kulkarni; Christiane Schuchardt; Aviral Singh; Martina Wirtz; Stefan Wiessalla; Margret Schottelius; Dirk Mueller; Ingo Klette; Hans-Jürgen Wester
Journal:  J Nucl Med       Date:  2016-01-21       Impact factor: 10.057

9.  68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer.

Authors:  Wolfgang P Fendler; Dorothea F Schmidt; Vera Wenter; Kolja M Thierfelder; Christian Zach; Christian Stief; Peter Bartenstein; Thomas Kirchner; Franz J Gildehaus; Christian Gratzke; Claudius Faber
Journal:  J Nucl Med       Date:  2016-06-03       Impact factor: 10.057

10.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.